{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T06:49:38Z","timestamp":1782024578479,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,14]]},"DOI":"10.7759\/cureus.84075","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:34:27Z","timestamp":1747208067000},"source":"Crossref","is-referenced-by-count":2,"title":["Deucravacitinib Treatment for Psoriasis Complicated by Myelodysplastic Syndrome Without Exacerbation of the Underlying Hematologic Disorder: A Case Report"],"prefix":"10.7759","author":[{"given":"Yoshihito","family":"Mima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Iozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb JE","year":"2016","unstructured":"Greb JE, Goldminz AM, Elder JT, et al.. Psoriasis. Nat Rev Dis Primers. 2016, 2:16082. 10.1038\/nrdp.2016.82","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi R","year":"2013","unstructured":"Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013, 133:377-85. 10.1038\/jid.2012.339","journal-title":"J Invest Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong AW","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020, 323:1945-60. 10.1001\/jama.2020.4006","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita J","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017, 76:377-90. 10.1016\/j.jaad.2016.07.064","journal-title":"J Am Acad Dermatol"},{"key":"ref5","article-title":"Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine","volume":"33","author":"Alwan W","year":"2015","unstructured":"Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol. 2015, 33:S2-6.","journal-title":"Clin Exp Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes JE","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018, 201:1605-13. 10.4049\/jimmunol.1800013","journal-title":"J Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15913","article-title":"Pathophysiology of psoriasis: a review","volume":"48","author":"Yamanaka K","year":"2021","unstructured":"Yamanaka K, Yamamoto O, Honda T. Pathophysiology of psoriasis: a review. J Dermatol. 2021, 48:722-31. 10.1111\/1346-8138.15913","journal-title":"J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi K","year":"2021","unstructured":"Ghoreschi K, Balato A, Enerb\u00e4ck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021, 397:754-66. 10.1016\/S0140-6736(21)00184-7","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong AW","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, et al.. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023, 88:29-39. 10.1016\/j.jaad.2022.07.002","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2008240","article-title":"TYK2 inhibition: changing the treatment landscape for psoriasis?","volume":"18","author":"Abduelmula A","year":"2022","unstructured":"Abduelmula A, Gooderham MJ. TYK2 inhibition: changing the treatment landscape for psoriasis?. Expert Rev Clin Immunol. 2022, 18:185-7. 10.1080\/1744666X.2022.2008240","journal-title":"Expert Rev Clin Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)90232-5","article-title":"Unusual specific cutaneous lesions in myelodysplastic syndromes","volume":"33","author":"Aractingi S","year":"1995","unstructured":"Aractingi S, Bachmeyer C, Miclea JM, V\u00e9rola O, Rousselot P, Dubertret L, Daniel MT. Unusual specific cutaneous lesions in myelodysplastic syndromes. J Am Acad Dermatol. 1995, 33:187-91. 10.1016\/0190-9622(95)90232-5","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17570","article-title":"Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: patient-reported outcomes in the POETYK PSO-4 study","volume":"52","author":"Tada Y","year":"2025","unstructured":"Tada Y, Armstrong AW, Imafuku S, et al.. Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: patient-reported outcomes in the POETYK PSO-4 study. J Dermatol. 2025, 52:353-8. 10.1111\/1346-8138.17570","journal-title":"J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.08.009","article-title":"Use of TYK2 inhibitor to relieve reactive granulomatous dermatitis due to myelodysplastic syndrome","volume":"40","author":"Huang C","year":"2023","unstructured":"Huang C, Berghoff A, Arbiser JL. Use of TYK2 inhibitor to relieve reactive granulomatous dermatitis due to myelodysplastic syndrome. JAAD Case Rep. 2023, 40:41-4. 10.1016\/j.jdcr.2023.08.009","journal-title":"JAAD Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.08.018","article-title":"Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence","volume":"31","author":"Shide K","year":"2007","unstructured":"Shide K, Shimoda K, Kamezaki K, et al.. Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence. Leuk Res. 2007, 31:1077-84. 10.1016\/j.leukres.2006.08.018","journal-title":"Leuk Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.14985","article-title":"Age-associated myeloid malignancies - the role of STAT3 and STAT5 in myelodysplastic syndrome and acute myeloid leukemia","volume":"598","author":"Fasouli ES","year":"2024","unstructured":"Fasouli ES, Katsantoni E. Age-associated myeloid malignancies - the role of STAT3 and STAT5 in myelodysplastic syndrome and acute myeloid leukemia. FEBS Lett. 2024, 598:2809-28. 10.1002\/1873-3468.14985","journal-title":"FEBS Lett"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.10.015","article-title":"Tyrosine kinase 2 - surveillant of tumours and bona fide oncogene","volume":"89","author":"Leitner NR","year":"2017","unstructured":"Leitner NR, Witalisz-Siepracka A, Strobl B, M\u00fcller M. Tyrosine kinase 2 - surveillant of tumours and bona fide oncogene. Cytokine. 2017, 89:209-18. 10.1016\/j.cyto.2015.10.015","journal-title":"Cytokine"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16590","article-title":"The implication of 'unknown significance' variants in next-generation sequencing in diagnosis and donor selection for allogenic haematopoietic stem cell transplantation. Report of a case of myelodysplastic syndrome with a polymorphism in the tyrosine kinase 2 (TYK2) gene","volume":"189","author":"L\u00f3pez-Andrade B","year":"2020","unstructured":"L\u00f3pez-Andrade B, Bento L, Diez Campelo M, et al.. The implication of 'unknown significance' variants in next-generation sequencing in diagnosis and donor selection for allogenic haematopoietic stem cell transplantation. Report of a case of myelodysplastic syndrome with a polymorphism in the tyrosine kinase 2 (TYK2) gene. Br J Haematol. 2020, 189:e182-4. 10.1111\/bjh.16590","journal-title":"Br J Haematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/367013-deucravacitinib-treatment-for-psoriasis-complicated-by-myelodysplastic-syndrome-without-exacerbation-of-the-underlying-hematologic-disorder-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:34:27Z","timestamp":1747208067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/367013-deucravacitinib-treatment-for-psoriasis-complicated-by-myelodysplastic-syndrome-without-exacerbation-of-the-underlying-hematologic-disorder-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.84075","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,14]]}}}